vs
Orthofix Medical Inc.（OFIX）与PROGRESS SOFTWARE CORP（PRGS）财务数据对比。点击上方公司名可切换其他公司
PROGRESS SOFTWARE CORP的季度营收约是Orthofix Medical Inc.的1.1倍（$252.7M vs $219.9M），PROGRESS SOFTWARE CORP净利率更高（10.2% vs -1.0%，领先11.2%），PROGRESS SOFTWARE CORP同比增速更快（17.5% vs 2.0%），PROGRESS SOFTWARE CORP自由现金流更多（$59.9M vs $16.8M），过去两年PROGRESS SOFTWARE CORP的营收复合增速更高（17.0% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Progress Software是全球领先的企业级软件服务商，主营应用开发平台、数据连接工具、数字体验解决方案等产品，服务覆盖金融、医疗、制造、零售等多行业的全球企业客户，助力客户搭建高性能可扩展的业务应用，提升运营效率。
OFIX vs PRGS — 直观对比
营收规模更大
PRGS
是对方的1.1倍
$219.9M
营收增速更快
PRGS
高出15.6%
2.0%
净利率更高
PRGS
高出11.2%
-1.0%
自由现金流更多
PRGS
多$43.1M
$16.8M
两年增速更快
PRGS
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $252.7M |
| 净利润 | $-2.2M | $25.7M |
| 毛利率 | 71.1% | 81.6% |
| 营业利润率 | 0.2% | 15.2% |
| 净利率 | -1.0% | 10.2% |
| 营收同比 | 2.0% | 17.5% |
| 净利润同比 | 92.4% | 2144.6% |
| 每股收益（稀释后） | $-0.05 | $0.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXPRGS
| Q4 25 | $219.9M | $252.7M | ||
| Q3 25 | $205.6M | $249.8M | ||
| Q2 25 | $203.1M | $237.4M | ||
| Q1 25 | $193.6M | $238.0M | ||
| Q4 24 | $215.7M | $215.0M | ||
| Q3 24 | $196.6M | $178.7M | ||
| Q2 24 | $198.6M | $175.1M | ||
| Q1 24 | $188.6M | $184.7M |
净利润OFIXPRGS
| Q4 25 | $-2.2M | $25.7M | ||
| Q3 25 | $-22.8M | $19.4M | ||
| Q2 25 | $-14.1M | $17.0M | ||
| Q1 25 | $-53.1M | $10.9M | ||
| Q4 24 | $-29.1M | $1.1M | ||
| Q3 24 | $-27.4M | $28.5M | ||
| Q2 24 | $-33.4M | $16.2M | ||
| Q1 24 | $-36.0M | $22.6M |
毛利率OFIXPRGS
| Q4 25 | 71.1% | 81.6% | ||
| Q3 25 | 72.2% | 81.0% | ||
| Q2 25 | 68.7% | 80.1% | ||
| Q1 25 | 62.8% | 80.6% | ||
| Q4 24 | 69.0% | 83.0% | ||
| Q3 24 | 68.7% | 83.7% | ||
| Q2 24 | 67.8% | 81.7% | ||
| Q1 24 | 67.5% | 82.2% |
营业利润率OFIXPRGS
| Q4 25 | 0.2% | 15.2% | ||
| Q3 25 | -8.3% | 17.6% | ||
| Q2 25 | -7.9% | 16.3% | ||
| Q1 25 | -25.2% | 13.6% | ||
| Q4 24 | -5.3% | 10.0% | ||
| Q3 24 | -9.6% | 22.6% | ||
| Q2 24 | -12.5% | 15.5% | ||
| Q1 24 | -15.6% | 19.0% |
净利率OFIXPRGS
| Q4 25 | -1.0% | 10.2% | ||
| Q3 25 | -11.1% | 7.8% | ||
| Q2 25 | -6.9% | 7.2% | ||
| Q1 25 | -27.4% | 4.6% | ||
| Q4 24 | -13.5% | 0.5% | ||
| Q3 24 | -13.9% | 15.9% | ||
| Q2 24 | -16.8% | 9.2% | ||
| Q1 24 | -19.1% | 12.3% |
每股收益（稀释后）OFIXPRGS
| Q4 25 | $-0.05 | $0.59 | ||
| Q3 25 | $-0.57 | $0.44 | ||
| Q2 25 | $-0.36 | $0.39 | ||
| Q1 25 | $-1.35 | $0.24 | ||
| Q4 24 | $-0.76 | $0.01 | ||
| Q3 24 | $-0.71 | $0.65 | ||
| Q2 24 | $-0.88 | $0.37 | ||
| Q1 24 | $-0.95 | $0.51 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $94.8M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $450.0M | $478.3M |
| 总资产 | $850.6M | $2.5B |
| 负债/权益比越低杠杆越低 | — | 2.93× |
8季度趋势，按日历期对齐
现金及短期投资OFIXPRGS
| Q4 25 | $82.0M | $94.8M | ||
| Q3 25 | $62.9M | $99.0M | ||
| Q2 25 | $65.6M | $102.0M | ||
| Q1 25 | $58.0M | $124.2M | ||
| Q4 24 | $83.2M | $118.1M | ||
| Q3 24 | $30.1M | $232.7M | ||
| Q2 24 | $26.4M | $190.4M | ||
| Q1 24 | $27.0M | $133.2M |
总债务OFIXPRGS
| Q4 25 | — | $1.4B | ||
| Q3 25 | $157.2M | $1.4B | ||
| Q2 25 | $157.0M | $1.5B | ||
| Q1 25 | $156.9M | $1.5B | ||
| Q4 24 | $157.0M | $1.5B | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXPRGS
| Q4 25 | $450.0M | $478.3M | ||
| Q3 25 | $442.5M | $477.7M | ||
| Q2 25 | $458.3M | $452.7M | ||
| Q1 25 | $458.3M | $431.8M | ||
| Q4 24 | $503.1M | $438.8M | ||
| Q3 24 | $525.9M | $425.6M | ||
| Q2 24 | $546.0M | $401.7M | ||
| Q1 24 | $570.3M | $461.7M |
总资产OFIXPRGS
| Q4 25 | $850.6M | $2.5B | ||
| Q3 25 | $832.6M | $2.4B | ||
| Q2 25 | $837.2M | $2.4B | ||
| Q1 25 | $823.1M | $2.5B | ||
| Q4 24 | $893.3M | $2.5B | ||
| Q3 24 | $867.9M | $1.6B | ||
| Q2 24 | $882.0M | $1.6B | ||
| Q1 24 | $906.0M | $1.5B |
负债/权益比OFIXPRGS
| Q4 25 | — | 2.93× | ||
| Q3 25 | 0.36× | 2.97× | ||
| Q2 25 | 0.34× | 3.22× | ||
| Q1 25 | 0.34× | 3.50× | ||
| Q4 24 | 0.31× | 3.48× | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $62.8M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $59.9M |
| 自由现金流率自由现金流/营收 | 7.6% | 23.7% |
| 资本支出强度资本支出/营收 | 4.9% | 1.1% |
| 现金转化率经营现金流/净利润 | — | 2.44× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $229.5M |
8季度趋势，按日历期对齐
经营现金流OFIXPRGS
| Q4 25 | $27.7M | $62.8M | ||
| Q3 25 | $12.4M | $73.4M | ||
| Q2 25 | $11.6M | $30.0M | ||
| Q1 25 | $-18.4M | $68.9M | ||
| Q4 24 | $23.7M | $19.7M | ||
| Q3 24 | $11.7M | $57.7M | ||
| Q2 24 | $9.0M | $63.7M | ||
| Q1 24 | $-18.6M | $70.5M |
自由现金流OFIXPRGS
| Q4 25 | $16.8M | $59.9M | ||
| Q3 25 | $2.5M | $72.4M | ||
| Q2 25 | $4.5M | $29.5M | ||
| Q1 25 | $-25.1M | $67.7M | ||
| Q4 24 | $15.2M | $16.8M | ||
| Q3 24 | $6.3M | $56.6M | ||
| Q2 24 | $-360.0K | $62.7M | ||
| Q1 24 | $-29.1M | $70.2M |
自由现金流率OFIXPRGS
| Q4 25 | 7.6% | 23.7% | ||
| Q3 25 | 1.2% | 29.0% | ||
| Q2 25 | 2.2% | 12.4% | ||
| Q1 25 | -13.0% | 28.4% | ||
| Q4 24 | 7.0% | 7.8% | ||
| Q3 24 | 3.2% | 31.7% | ||
| Q2 24 | -0.2% | 35.8% | ||
| Q1 24 | -15.4% | 38.0% |
资本支出强度OFIXPRGS
| Q4 25 | 4.9% | 1.1% | ||
| Q3 25 | 4.8% | 0.4% | ||
| Q2 25 | 3.5% | 0.2% | ||
| Q1 25 | 3.5% | 0.5% | ||
| Q4 24 | 4.0% | 1.3% | ||
| Q3 24 | 2.7% | 0.6% | ||
| Q2 24 | 4.7% | 0.5% | ||
| Q1 24 | 5.6% | 0.2% |
现金转化率OFIXPRGS
| Q4 25 | — | 2.44× | ||
| Q3 25 | — | 3.78× | ||
| Q2 25 | — | 1.76× | ||
| Q1 25 | — | 6.30× | ||
| Q4 24 | — | 17.13× | ||
| Q3 24 | — | 2.03× | ||
| Q2 24 | — | 3.93× | ||
| Q1 24 | — | 3.11× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
PRGS
| Maintenanceand Services | $187.5M | 74% |
| Share File Acquisition | $67.5M | 27% |
